Safety and Efficacy of Bimatoprost Solution 0.03% (Topical Application in Patients with Chemotherapy-Induced Eyelash Loss)

Few dermatologic conditions carry  as much anxiety and  emotional distress as hair  loss  resulting from  a disease condition such as alopecia areata or as a result of cytotoxic drug treatment, e.g., after  chemotherapy. Bimatoprost

0.03% solution is a Food and Drug Administration-approved prescription product indicated for the treatment of

Eyelash hypotrichosis. The  product was  investigated in a double-masked, randomized, and  placebo-controlled study in  patients who  had  significant eyelash loss  or  hypotrichosis as  a  result of  chemotherapy. Once-daily treatment with bimatoprost ophthalmic solution 0.03% to the upper eyelid margin restored eyelash growth and prominence more quickly than the slower, natural course of recovery observed in the vehicle control subjects. The eyelash prominence measured using a validated Global Eyelash Assessment (GEA) scale demonstrated a statistically significant increase over placebo following 6 months of treatment. Efficacy was also demonstrated using a validated objective digital image analysis methodology to show significant increase in eyelash length, thickness/fullness, and darkness in these patients. Bimatoprost was found to be well tolerated over the 1-year treatment period.